[1] Dev S, Kruse R L, Hamilton J P, et al. Wilson disease: update on pathophysiology and treatment[J]. Front Cell Dev Biol, 2022, 10: 871877. [2] Shribman S, Poujois A, Bandmann O, et al. Wilson's disease: update on pathogenesis, biomarkers and treatments[J]. J Neurol Neurosurg Psychiatry, 2021, 92(10):1053-1061. [3] Dzieżyc K, Litwin T, Członkowska A. Other organ involvement and clinical aspects of Wilson disease[J]. Handb Clin Neurol, 2017, 142: 157-169. [4] Bhattacharya K, Thankappan B. Wilson's disease update: an Indian perspective[J]. Ann Indian Acad Neurol, 2022, 25(1): 43-53. [5] Linz R, Lutsenko S. Copper-transporting ATPases ATP7A and ATP7B: cousins, not twins[J]. J Bioenerg Biomembr, 2007, 39(5-6):403-407. [6] Lutsenko S. Copper trafficking to the secretory pathway[J]. Metallomics, 2016, 8(9):840-852. [7] Jiang S, Li H, Zhang L, et al. Generic diagramming platform (GDP): a comprehensive database of high-quality biomedical graphics[J]. Nucleic Acids Res, 2025, 53(D1): D1670-D1676. [8] Linz R, Barnes N L, Zimnicka A M, et al. Intracellular targeting of copper-transporting ATPase ATP7A in a normal and Atp7b-/-kidney[J]. Am J Physiol Renal Physiol,2008, 294(1): F53-F61. [9] Bearn A G, Yu T F, Gutman A B. Renal function in Wilson's disease[J]. J Clin Invest, 1957, 36(7): 1107-1114. [10] Habib G S, Saliba W, Nashashibi M, et al. Penicillamine and nephrotic syndrome[J]. Eur J Intern Med, 2006, 17(5): 343-348. [11] Dang J, Chevalier K, Letavernier E, et al. Kidney involvement in Wilson's disease: a review of the literature[J]. Clin Kidney J, 2024, 17(4): sfae058. [12] Matti M R, Mohan A, Maralihalli M, et al. Unusual presentation of Wilson's disease as proximal renal tubular acidosis with isolated phosphaturia[J]. BMJ Case Rep, 2024, 17(9): e260027. [13] Selvan C, Thukral A, Chakraborthy P P, et al. Refractory rickets due to Fanconi's syndrome secondary to Wilson's disease[J]. Indian J Endocrinol Metab, 2012, 16(Suppl 2): S399-S401. [14] Palkar A V, Shrivastava M S, Padwal N J, et al. Renal tubular acidosis due to Wilson's disease presenting as metabolic bone disease[J]. BMJ Case Rep, 2011,2011:bcr0420114121. [15] Cooper A M, Eckhardt R D, Faloon W W, et al. Investigation of the aminoaciduria in Wilson's disease (hepatolenticular degeneration): demonstration of a defect in renal function[J]. J Clin Invest, 1950, 29(3): 265-278. [16] Jin S, Sun Z, Fang X, et al. Characterization of renal damage in Wilson's disease-Detailed analysis of 20 Chinese cases[J]. Med Clin (Barc), 2024, 163(7): 360-366. [17] Xu H, Lv H, Chen X, et al. Novel mutations in ATP7B in Chinese patients with Wilson's disease and identification of kidney disorder of thinning of the glomerular basement membrane[J]. Front Neurol, 2023, 14: 1231605. [18] Weitzman E, Pappo O, Weiss P, et al. Late onset fulminant Wilson's disease: a case report and review of the literature[J]. World J Gastroenterol, 2014, 20(46): 17656-17660. [19] Leung M, Wu Lanzafame J, Medici V. Switching pharmacological treatment in Wilson disease: case report and recommendations[J]. J Investig Med High Impact Case Rep, 2020, 8: 2324709619896876. [20] Weiss K H, Thurik F, Gotthardt D N, et al. Efficacy and safety of oral chelators in treatment of patients with Wilson's disease[J]. Clin Gastroenterol Hepatol, 2013, 11(8):1028-1035. |